Cargando…

Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study

The objective of the present study was to investigate the tumor-associated vascular changes in hepatocellular carcinoma (HCC) following treatment with transarterial chemoembolization (TACE) combined with sorafenib. The data of 20 patients were retrospectively analyzed. Patients underwent treatment d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ligang, Zheng, Yifei, Zhang, Hongjian, Pan, Heng, Liu, Qiusong, Zhou, Xu, Wei, Wei, Liu, Yun, Zhen, Maochuan, Wang, Jinling, Zhou, Jianyin, Zhao, Yilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096284/ https://www.ncbi.nlm.nih.gov/pubmed/30127979 http://dx.doi.org/10.3892/ol.2018.9055

Ejemplares similares

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study
por: Yao, Qi, et al.
Publicado: (2017)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor in Combination with a Collagen Matrix in Chronic Hindlimb Ischemia
por: Zhou, Jianyin, et al.
Publicado: (2012)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

The development of an extra-anatomic tissue-engineered artery with collateral arteries for therapeutic angiogenesis in ischemic hind limb
por: Zhou, Xu, et al.
Publicado: (2018)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
por: Qu, Xu-Dong, et al.
Publicado: (2012)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Vascular anomalies of the celiac trunk and implications in treatment of HCC with TACE. Description of a case and review of the literature
por: Roma, Silvia, et al.
Publicado: (2019)

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib
por: Shen, Lujun, et al.
Publicado: (2018)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Efficacy of TACE+Radiofrequency Ablation+Sorafenib in the Treatment of Patients with Recurrent Liver Cancer and Construction of Prediction Model
por: Sun, Aimin, et al.
Publicado: (2022)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
por: Féray, Cyrille, et al.
Publicado: (2023)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?
por: Adhoute, Xavier, et al.
Publicado: (2020)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_batdfd6pai57q9agdf25rc8mv3